Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06371404 · ClinicalTrials.gov registry record
Imaging Traumatic Stress and Alcohol Use Disorder With [18F]Bavarostat
A clinical trial of Alcohol Use Disorder and Post Traumatic Stress Disorder, sponsored by Yale University.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT06371404 is a study of Alcohol Use Disorder and Post Traumatic Stress Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 150 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06371404, a study of Alcohol Use Disorder and Post Traumatic Stress Disorder, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall objective of this study it to use Positron Emission Tomography (PET) brain imaging and a radiotracer that measures the epigenetic marker Histone Deacetylase 6 (HDAC6) to examine HDAC6 expression in people with Post-Traumatic Stress Disorder (PTSD), Alcohol Use Disorder (AUD), or concurrent PTSD and AUD with control groups. While there are a large number of studies conducted in preclinical stress and addiction models, these findings have not been translated to people living with these disorders. This study will examine relationships between HDAC6 and clinical variables of interest. Findings could direct treatment development.
Conditions Studied
Interventions
- DRUG Bavarostat
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-06-05 |
| Est. Completion | 2031-06-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06371404
The ClinicalTrials.gov registry entry for NCT06371404 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (54% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alcohol Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Bavarostat is the first listed.
NCT06371404 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT06371404 about?
NCT06371404 is a clinical study titled "Imaging Traumatic Stress and Alcohol Use Disorder With [18F]Bavarostat". The overall objective of this study it to use Positron Emission Tomography (PET) brain imaging and a radiotracer that measures the epigenetic marker Histone Deacetylase 6 (HDAC6) to examine HDAC6 expression in people with Post-Traumatic Stress Disorder (PTSD), Alcohol Use Disorder (AUD), or concurre...
What is the current status of trial NCT06371404?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2024-06-05. Estimated completion is 2031-06-01.
What conditions does trial NCT06371404 study?
This clinical trial studies the following conditions: Alcohol Use Disorder, Post Traumatic Stress Disorder.
What interventions are being tested in trial NCT06371404?
The interventions under investigation include: Bavarostat (DRUG).
Who is sponsoring clinical trial NCT06371404?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06371404 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
RECRUITING · Phase 2
-
Ultrasound Neuromodulation of the Brain for Alcohol Use Disorder
RECRUITING · NA
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
RECRUITING · NA
-
AAT for Alcohol Use Disorder in Veterans
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.